These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

870 related items for PubMed ID: 25801001

  • 1. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S, Jones PG, Maddox TM, Bradley SM, Stolker JM, Arnold SV, Parashar S, Peterson P, Bhatt DL, Spertus J, Ho PM.
    Heart; 2015 May 15; 101(10):800-7. PubMed ID: 25801001
    [Abstract] [Full Text] [Related]

  • 2. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
    Halvorsen S, Jortveit J, Hasvold P, Thuresson M, Øie E.
    BMC Cardiovasc Disord; 2016 May 31; 16():115. PubMed ID: 27246583
    [Abstract] [Full Text] [Related]

  • 3. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS, Saad A, Al-Suwaidi J, Al-Marridi WZ, Elkhalifa DH, Mohamed AA, Mahfoud ZR.
    Curr Vasc Pharmacol; 2016 May 31; 14(4):394-403. PubMed ID: 26916397
    [Abstract] [Full Text] [Related]

  • 4. Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    Makam RC, Erskine N, McManus DD, Lessard D, Gore JM, Yarzebski J, Goldberg RJ.
    Am J Cardiol; 2016 Dec 15; 118(12):1792-1797. PubMed ID: 27743577
    [Abstract] [Full Text] [Related]

  • 5. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study.
    Mathews R, Wang TY, Honeycutt E, Henry TD, Zettler M, Chang M, Fonarow GC, Peterson ED, TRANSLATE-ACS Study Investigators.
    Am Heart J; 2015 Jul 15; 170(1):62-9. PubMed ID: 26093865
    [Abstract] [Full Text] [Related]

  • 6. Chronic polytherapy after myocardial infarction: the trade-off between hospital and community-based providers in determining adherence to medication.
    Di Martino M, Alagna M, Lallo A, Gilmore KJ, Francesconi P, Profili F, Scondotto S, Fantaci G, Trifirò G, Isgrò V, Davoli M, Fusco D.
    BMC Cardiovasc Disord; 2021 Apr 14; 21(1):180. PubMed ID: 33853534
    [Abstract] [Full Text] [Related]

  • 7. Medication use in long-term survivors from the MONICA/KORA Myocardial Infarction Registry.
    Amann U, Kirchberger I, Heier M, Thilo C, Kuch B, Meisinger C.
    Eur J Intern Med; 2018 Jan 14; 47():62-68. PubMed ID: 28826823
    [Abstract] [Full Text] [Related]

  • 8. Optimal secondary prevention medication use in acute myocardial infarction patients with nonobstructive coronary artery disease is modified by management strategy: insights from the TRIUMPH Registry.
    Pitts R, Daugherty SL, Tang F, Jones P, Ho PM, Tsai TT, Spertus J, Maddox TM.
    Clin Cardiol; 2017 Jun 14; 40(6):347-355. PubMed ID: 28387960
    [Abstract] [Full Text] [Related]

  • 9. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry.
    Urbinati S, Olivari Z, Gonzini L, Savonitto S, Farina R, Del Pinto M, Valbusa A, Fantini G, Mazzoni A, Maggioni AP, BLITZ-4 Investigators.
    Eur J Prev Cardiol; 2015 Dec 14; 22(12):1548-56. PubMed ID: 25452625
    [Abstract] [Full Text] [Related]

  • 10. Adherence to ACC/AHA performance measures for myocardial infarction in six Middle-Eastern countries: association with in-hospital mortality and clinical characteristics.
    Longenecker JC, Alfaddagh A, Zubaid M, Rashed W, Ridha M, Alenezi F, Alhamdan R, Akbar M, Bulbanat BY, Al-Suwaidi J.
    Int J Cardiol; 2013 Aug 20; 167(4):1406-11. PubMed ID: 22578736
    [Abstract] [Full Text] [Related]

  • 11. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction.
    Arnold SV, Spertus JA, Masoudi FA, Daugherty SL, Maddox TM, Li Y, Dodson JA, Chan PS.
    J Am Coll Cardiol; 2013 Nov 05; 62(19):1791-801. PubMed ID: 23973701
    [Abstract] [Full Text] [Related]

  • 12. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U, Kirchberger I, Heier M, Zirngibl A, von Scheidt W, Kuch B, Peters A, Meisinger C.
    Am J Cardiol; 2014 Aug 01; 114(3):329-35. PubMed ID: 24927969
    [Abstract] [Full Text] [Related]

  • 13. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B, Musić L, Batrićević G, Bošković A, Bulatović N, Nenezić A, Vujović J, Kalezić M.
    Int J Cardiol; 2016 Aug 01; 217 Suppl():S32-6. PubMed ID: 27381861
    [Abstract] [Full Text] [Related]

  • 14. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY, Cooke CE, Robertson TA.
    J Manag Care Pharm; 2008 Apr 01; 14(3):271-80. PubMed ID: 18439049
    [Abstract] [Full Text] [Related]

  • 15. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program.
    Xie JX, Gunzburger EC, Kaun L, Plomondon ME, Barón AE, Waldo SW, Virani SS, Maddox TM, Mavromatis K.
    Circ Cardiovasc Qual Outcomes; 2019 Nov 01; 12(11):e005455. PubMed ID: 31665896
    [Abstract] [Full Text] [Related]

  • 16. Long-term secondary prevention of acute myocardial infarction (SEPAT) - guidelines adherence and outcome.
    Ergatoudes C, Thunström E, Rosengren A, Björck L, Bengtsson Boström K, Falk K, Fu M.
    BMC Cardiovasc Disord; 2016 Nov 17; 16(1):226. PubMed ID: 27855640
    [Abstract] [Full Text] [Related]

  • 17. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization.
    Thiney M, Della Schiava N, Ecochard R, Feugier P, Lermusiaux P, Millon A, Long A.
    Ann Vasc Surg; 2018 Oct 17; 52():138-146. PubMed ID: 29777848
    [Abstract] [Full Text] [Related]

  • 18. Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
    Bruggmann C, Iglesias JF, Gex-Fabry M, Fesselet R, Vogt P, Sadeghipour F, Voirol P.
    Am J Cardiovasc Drugs; 2020 Feb 17; 20(1):105-115. PubMed ID: 31300969
    [Abstract] [Full Text] [Related]

  • 19. Secondary medical prevention among Danish patients hospitalised with either peripheral arterial disease or myocardial infarction.
    Gasse C, Jacobsen J, Larsen AC, Schmidt EB, Johannesen NL, Videbaek J, Sørensen HT, Johnsen SP.
    Eur J Vasc Endovasc Surg; 2008 Jan 17; 35(1):51-8. PubMed ID: 17923426
    [Abstract] [Full Text] [Related]

  • 20. Association of hospital myocardial infarction volume with adherence to American College of Cardiology/American Heart Association performance measures: Insights from the National Cardiovascular Data Registry.
    Harrison RW, Simon D, Miller AL, de Lemos JA, Peterson ED, Wang TY.
    Am Heart J; 2016 Aug 17; 178():95-101. PubMed ID: 27502856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.